| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Pulmonary hypertension (PH) is a rare non-curable disease that results in death due to right heart failure, and treatment to improve right heart function is an unsolved issue. In this study, we established an evaluation method focusing on the progressive mechanisms of right heart in the patient with PH. More than 50% of patients with chronic thromboembolic pulmonary hypertension after treatment with balloon pulmonary angioplasty had right heart dysfunction. QRS width on electrocardiogram could be a predictor and may reflect right ventricular fibrosis. In addition, the right heart function was evaluated using the T1 mapping method of cardiac MRI in the patient with PH. It was associated with BNP and right ventricular contractility index, and was also associated with the prediction of residual low right ventricular ejection fraction and the events. This research show T1 value could be a novel imaging biomarker for the patients with PH.
|
